| 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 君实生物(01877) | 22.860 | 40.09 | 110.06% | 22.43% | | 京城机电股份 (00187) | 4.130 | 13.08 | 279.42% | 22.18% | | 康希诺生物(06185) | 36.740 | 73.16 | 138.51% | 21.90% | | 金风科技(02208) | 15.580 | 28.12 | 116.17% | 19.35% | | 安德利果汁(02218) | 15.500 | 44.77 | 246.00% | 19.04% | | 东北电气(00042) | 0.285 | 2.25 | 847.37% | 11.94% | | | 15.370 | 30.1 | 134.55% | 10.75% | | 广和通(00638) | | | | | | --- | --- | --- | --- | --- | | 洛阳钼业(03993) | 24.140 | 26.88 | 33. ...

今日（1.28），沪指再度收涨，医药板块回调，医药ETF（159929）收跌1.16%，全天成交额超1.2亿元！资金逢跌布局，全天净流入近6000万元，近 10日累计"吸金"超2.8亿元。 消息面上，药监局近日批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》、《采用脑机接口技术的医疗器械侵入式设备可靠性 验证方法》等2项医疗器械行业标准制修订项目立项。 医药ETF（159929）标的指数权重股多数收绿：联影医疗跌超3%，迈瑞医疗跌超2%，恒瑞医药、云南白药跌超1%，药明康德、爱尔眼科、片仔癀微 跌。 | 序号 | 代码 | 名称 | 估算权重 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 603259 | 药明康德 | 10.59% | -0.09% | 43.61 Z | | 2 | 600276 | 恒瑞医药 | 9.07% | -1.14% | 49.93亿 | | 3 | 300760 | 迈瑞医疗 | 5.54% | -2.13% | 27.10亿 | | 4 | 688271 | 联影医疗 | 3.33% | - ...

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their products, with significant business development (BD) transactions announced[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% increase year-on-year, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise, with a projected increase of 33-38% for NAND Flash products due to supply constraints[36] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - The goal is to achieve a 30% share of renewable energy in total power generation by 2030, indicating significant growth potential for the solar and wind energy sectors[46]

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their advancements, with significant business development (BD) transactions reported[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% year-on-year increase, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise due to increased demand from AI servers, with NAND Flash supply expected to decrease by 41.7% in 2026[35] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - By 2030, renewable energy generation is expected to account for approximately 30% of total power generation, indicating significant growth potential in the solar and wind sectors[46]

华润啤酒-R(80291)、安踏体育-R(82020)、李宁-R(82331)上一交易日沽空比率位于前三位，分别为 100.00%、100.00%、100.00%。泡泡玛特(09992)、小米集团-W(01810)、阿里巴巴-W(09988)的沽空金额 位居前三，分别为12.09 亿元、10.75 亿元、9.74 亿元。中国中车(01766)、李宁-R(82331)、中国平安- R(82318)的偏离值位居前三，分别为42.51%、38.82%、30.07%。 前十大沽空比率排行 | 股票名称 | 沽空金额 | 沽空比率↓ | 偏离值 | | --- | --- | --- | --- | | 华润啤酒-R(80291) | 19.28 万元 | 100.00% | 25.37% | | 安踏体育-R(82020) | 9.50 万元 | 100.00% | 12.50% | | 李宁-R(82331) | 10.09 万元 | 100.00% | 38.82% | | 联想集团-R(80992) | 456.22 万元 | 82.43% | 2.97% | | 中国平安-R(82318) | 397.47 ...

友邦保险-R(81299)、京东健康-R(86618)、百度集团-SWR(89888)上一交易日沽空比率位于前三位，分别 为100.00%、100.00%、95.46%。泡泡玛特(09992)、阿里巴巴-W(09988)、小米集团-W(01810)的沽空金 额位居前三，分别为13.00 亿元、12.60 亿元、10.64 亿元。百度集团-SWR(89888)、深圳高速公路股份 (00548)、商汤-WR(80020)的偏离值位居前三，分别为62.11%、37.02%、34.65%。 前十大沽空比率排行 前十大沽空偏离值排行 | 股票名称 | 沽空金额 | 沽空比率 | 偏离值↓ | | --- | --- | --- | --- | | 百度集团-SWR(89888) | 119.43 万元 | 95.46% | 62.11% | | 深圳高速公路股份(00548) | 164.67 万元 | 48.73% | 37.02% | | 商汤-WR(80020) | 15.48 万元 | 87.41% | 34.65% | | 中国平安-R(82318) | 245.20 万元 | 72.58% | 33.06% ...

Core Viewpoint - The article emphasizes China's dominant position in the global pharmaceutical supply chain, particularly in the production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which poses a significant asymmetric threat to U.S. national security [4][5]. Group 1: China's Dominance in Pharmaceutical Supply Chain - China holds a near-monopoly in the production of various pharmaceutical raw materials, with over 90% of global antibiotic intermediates supplied by China [18]. - Approximately 70%-80% of global vitamin production capacity is controlled by China, making it a critical player in the pharmaceutical industry [19]. - China's low-cost, high-output chemical manufacturing capabilities create significant barriers for competitors, allowing it to define prices and capacities in the market [21]. Group 2: Impact of Geopolitical Tensions - The U.S.-China trade tensions have led to concerns about the dependency of the U.S. on Chinese pharmaceutical supplies, which could lead to drug shortages in critical situations [9][10]. - The article illustrates a hypothetical scenario where geopolitical tensions could disrupt the supply of essential medications, highlighting the risks of "asymmetric interdependence" [7][9]. - The ongoing drug shortage issues in the U.S. are exacerbated by the complex global supply chain, where many active ingredients are sourced from China [10][11]. Group 3: Historical Context and Strategic Decisions - The article discusses the historical context of the pharmaceutical industry's shift, where Western companies outsourced low-margin API production to lower-cost countries, primarily China, while retaining high-margin R&D and marketing functions [23][24]. - This outsourcing has led to a significant loss of industrial capability in the West, as the foundational skills and infrastructure for API production have diminished [32]. Group 4: Challenges for India as an Alternative - India, often referred to as the "world's pharmacy," lacks the complete supply chain necessary for API production, relying heavily on Chinese intermediates [36][38]. - Despite efforts to establish a domestic API supply chain, India's progress is hindered by infrastructure challenges and the dominance of Chinese suppliers [37][39]. Group 5: Future Outlook and Strategic Recommendations - The article suggests that China is transitioning from merely being a low-cost producer to becoming a leader in technology and standards within the pharmaceutical industry [43]. - As geopolitical tensions rise, the need for China to innovate in green technologies and maintain its competitive edge in the pharmaceutical supply chain becomes critical [55][56]. - The future of the pharmaceutical industry will focus on balancing efficiency and safety, with the ability to provide cost-effective and safe drugs being a key determinant of success [58].

投资逻辑： 本周 Q4 公募基金医药持仓情况出炉，Q4 公募基金医药持仓占比为 8.11%，环比减少 1.66pp；剔除主动医药基金后， 公募基金医药持仓占比为3.90%，环比减少1.36pp。创新药ETF在Q4规模达到1006.2亿元，占医药基金比例为13.11%， 环比减少 1.35pp。创新药赛道在 25Q4 展现出了较强的韧性，其中单季医药基金/非药基金针对化学制剂持仓在医药 中占比+0.82%/-2.36%。受到地缘政治因素扰动，CXO 板块持仓比例有所下降。医疗设备赛道得益于脑机接口、手术机 器人等创新产品海外映射叠加政策支持，持仓占比有所提升。非药基金对中药有一定加仓，主要系部分中药公司股息 率较高，具备防守属性。基金对药店持仓总体相对平稳。从个股维度来看，恒瑞医药、信达生物等创新药企持股基金 数均有不同程度下降。药明康德四季度持股比例有一定下降，主要是由于地缘政治和股东减持因素影响。泰格医药持 股比例有一定提升，主要是由于国内市场转暖，订单和报价层面均逐步向好。 药品：1 月 20 日，GSK 宣布将以 22 亿美金收购 PART，强化布局 IgE 抗体等炎症和自免领域，预计 26Q1 将完成 ...

2026年1月16日，陈影从旧金山飞回上海，飞机上坐满了中国创新药企的创始人、高管、投资者，大部分人看上去心情不错，他们刚参加完全球规模最大的 医疗健康盛会——摩根大通医疗健康大会（下称"JPM"）。 这是陈影第一次参加JPM。2025年10月，她所在的赛默罗生物收到了几家跨国药企的邀请，希望能在JPM期间洽谈合作。赛默罗生物有一款原始创新（first- in-class）药物已进入临床二期试验，并获得美国食品药品监督管理局（FDA）的孤儿药认定，这引起了跨国药企的兴趣。 陈影此行与五六家跨国公司进行了一对一会谈，奔波在会场、各大洽谈室之间，每天睡觉不超过5小时。许多参会者都有类似体验，赫吉亚生物创始人崔坤 元开玩笑说，参会最直接的收获是"比较累"。大家期望在四天的日程里尽可能捕捉最前沿的行业信息、与意向合作方深入沟通。 多位受访者对经济观察报表示，相比前几年，2026年JPM带来的正向预期更明显。尤其是对中国创新药企，几乎每家跨国公司都不掩饰对中国资产的兴趣。 经济观察报 记者 张英 他观察到，尽管FDA官员在JPM期间提及了中美创新药竞争，但并未强调保护主义政策，更多提及的是美国医院、FDA如何优化临床试 ...

A股上市公司业绩预告加速披露。Wind数据显示，截至1月23日16时，A股共有710家上市公司对外披露 2025年全年业绩预告，284家预喜，预喜比例为40%。从报喜的上市公司所在行业角度看，有色金属、 半导体、生物医药、硬件设备、化工、汽车与零配件等行业表现亮眼。 ● 本报记者 董添 近70家企业净利同比增逾100% 南方精工预计2025年全年实现归属于上市公司股东的净利润为3亿元至3.7亿元，同比增长1130%至 1417%。报告期内，公司归属于上市公司股东的净利润增长，主要源于公司对持有的江苏泛亚微透科技 股份有限公司等投资项目进行了公允价值评估，产生的公允价值变动收益在本报告期对公司税前利润的 影响金额预计为3亿元至3.2亿元之间，该公允价值变动收益属于非经常性损益。 净利润数值方面，共有106家上市公司预计2025年归属于上市公司股东的净利润下限超过1亿元，49家预 计超过3亿元，33家预计超过5亿元，13家预计超过10亿元。紫金矿业、药明康德、洛阳钼业、立讯精 密、盐湖股份等公司预计2025年归属于上市公司股东的净利润数值居前。 药明康德预计2025年全年实现营业收入约为454.56亿元，同比增长 ...